CVRx Cuts Full-Year Revenue Guidance After Q3 Sales Slip 6%
CVRX sits 17% above its 52-week low of $1.255 on light trading volume (0.4× avg).
Summary
Q3 revenue came in at $13.8 million, down 6% from a year ago, with U.S. revenue of $13.0 million off 4% on lower sales force productivity and a prolonged challenge with one of its largest payers. Management cut full-year 2026 revenue guidance to $56.0-$57.0 million from $58.0-$60.0 million, and the Q4 guide of $11.7-$12.7 million implies a further sequential step down, with full-year gross margin guided to 86%-87% and operating expenses of $99-$101 million. The net loss widened to $14.2 million, or $0.52 per share, from $12.9 million a year earlier, while cash stood at $58.7 million against $11.0 million of quarterly cash burn. The lone bright spot is reimbursement: a second major Medicare Advantage payer issued a Barostim coverage policy, and the two policies together cover roughly 21% of MA enrollment. This lands after a rough stretch — the August CRO termination, a securities-fraud investigation, and activist Jorey Chernett exiting his 5.5% stake in October — so the guidance cut reinforces the execution concerns. New CFO John Landry starts November 6, and the 4:30 p.m. ET call today is where management will have to defend the demand shortfall.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — CVRx set Q4 2026 revenue guidance at $11.7-$12.7 million and full-year gross margin at 86%-87% with operating expenses of $99-$101 million.
At the time of this announcement, CVRX was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $1.26 to $10.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.